SCHEMBL20489035

SCHEMBL20489035

CC(=O)c1nn(CC(=O)OC(C)(C)C)c2cc(C(=O)OCc3ccccc3)ccc12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 4/20 0.44
▸ MAPT P10636 3/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ JMJD6 Q6NYC1 1/20 0.40
▸ RAB9A P51151 4/20 0.40
▸ LMNA P02545 4/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ SLC6A2 P23975 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ HPGD P15428 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ CFD P00746 4/20 0.37
▸ CNR2 P34972 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ GPR119 Q8TDV5 1/20 0.36
▸ GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12480120 0.88 LMNA (0.43) TDP1MAPTL3MBTL1JMJD6RAB9A
SCHEMBL12480283 0.88 MAPT (0.48) TDP1MAPTL3MBTL1JMJD6RAB9A
SCHEMBL25940602 0.88 TDP1 (0.48) TDP1MAPTL3MBTL1JMJD6RAB9A
SCHEMBL20487896 0.87 MAPT (0.42) TDP1MAPTL3MBTL1JMJD6RAB9A
SCHEMBL12479114 0.85 CFD (0.46) RAB9ALMNAKMT2AALDH1A1SMN1; SMN2
SCHEMBL20487924 0.85 CFD (0.43) ALDH1A1CFDKDM4E
SCHEMBL29855020 0.85 CFD (0.43) ALDH1A1CFDKDM4E
SCHEMBL29854934 0.80 ESR1 (0.37) LMNAKMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL12480155 0.79 KDM4E (0.48) LMNAKMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL25940512 0.78 CFD (0.37) MAPTLMNAKMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12297205-B2 Macrocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2025-05-13 — — US disclosed
US-20240059702-A1 MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2024-02-22 — — US disclosed
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-08-08 — — US disclosed
EP-3589287-B1 MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2022-09-14 — — EP disclosed
US-20210300934-A1 MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2021-09-30 — — US disclosed
US-11053253-B2 Macrocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2021-07-06 — — US disclosed
WO-2018160892-A1 MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2018-09-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders CFD, TFPI, CFH TDP1 4701/4885MAPT 3729/4885L3MBTL1 4664/4885
US-11053253-B2 Macrocyclic compounds for treatment of medical disorders CFD, TFPI, CFH TDP1 4701/4885MAPT 3729/4885L3MBTL1 4664/4885
US-20210300934-A1 MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS CFD, TFPI, CFH TDP1 4701/4885MAPT 3729/4885L3MBTL1 4664/4885
US-12297205-B2 Macrocyclic compounds for treatment of medical disorders CFD, TFPI, CFH TDP1 4701/4885MAPT 3729/4885L3MBTL1 4664/4885
US-20240059702-A1 MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS CFD, TFPI, CFH TDP1 4701/4885MAPT 3729/4885L3MBTL1 4664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback